EPHA2 and breast cancer: To assess CAR activity against target tumors, EphA2 CAR-NK92 cells were cocultured in vitro with three tumor cell lines: H460 (human lung cancer), MDA-MB-231 (human breast cancer), and K562 (Chronic Myelogenous Leukemia).